More work is ongoing to improve on t-dm1 based therapy. Following is an excerpt from a recently published world patent application:
"[159] As can be seen with reference to Figure 7, percent survival was dramatically higher when the agonist antibody (anti-CD137) was included, as compared with when an anti-tumor antibody (specifically trastuzumab or T-DM1 ) was utilized alone. Improved survival rates were observed for both trastuzumab and T-DM1 when agonist antibody was included. Moreover, Figure 6 documents the surprising finding that the improvement in percent survival achieved when anti- CD137 agonist therapy is added to T-DM1 therapy is dramatically more significant than that observed when anti-CD137 agonist therapy is added to trastuzumab therapy, notwithstanding that T-DM1 and trastuzumab target the same tumor antigen (HER2) and, moreover that T-DM1 includes the identical trastuzumab antibody, differing from trastuzumab in that the antibody is conjugated with DM1."
Hopefully Roche will apply this new methodology of treatment in a new clinical trial to translate these dramatical improvements into real life options.
https://worldwide.espacenet.com/publ...&locale=en_EP#